IFNA17 and chronic hepatitis C virus infection: The findings of a large randomized clinical trial of 1530 patients with chronic hepatitis C show a significantly higher SVR in the peg-IFN-α-2b plus ribavirin group than in the IFN-α-2b plus ribavirin group during initial treatment [34].